Oral dabigatran as effective as enoxaparin in preventing thromboprophylaxis after THA .
This report has been verified
by one or more authors of the
original publication.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial
Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 122055 patients undergoing total hip arthroplasty (THA) were randomized to receive oral dabigatran or subcutaneous enoxaparin to compare the impact each pharmaceutical had on the incidence of venous thromboembolism (VTE) and all-cause mortality. Following assessments over a 3 month period, the results displayed that both dabigatran and enoxaparin were equally effective in preventing VTE following THA. Additionally, the risk of bleeding and safety of both drugs were similar.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
